Abstract
We report a case of an infant with HIV receiving raltegravir granules for oral suspension and rifampicin-based TB prophylaxis. Raltegravir trough levels remained subtherapeutic and viral load increased during concurrent rifampicin therapy despite using double-dosed raltegravir. Even after rifampicin therapy, a higher dose was needed. This highlights the importance of therapeutic drug monitoring and dose adjustments of raltegravir in infants with rifampicin as comedication.
Cite
CITATION STYLE
van der Veer, M. A. A., Jacobs, T. G., Bukkems, L. H., Colbers, A. P. H., Burger, D. M., Scherpbier, H. J., & Bijleveld, Y. A. (2022). Pharmacokinetic interaction between raltegravir and rifampicin in an infant with HIV exposed to active TB: a case report. Antiviral Therapy, 27(4). https://doi.org/10.1177/13596535221119932
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.